Introduction
Adenosine 3':5'-cyclic monophosphate (cyclic AMP) and guanosine 3':5'-cyclic monophosphate (cyclic GMP) play an important role in the regulation of airway tone, elevations in either being causally associated with smooth muscle relaxation (Iscii & Murad, 1989; Murray, 1990; Torphy & Undem, 1991) .
Intracellular concentrations of cyclic nucleotides are determined by their relative rates of formation, via agonistinduced stimulation of adenylate and guanylate cyclase, and hydrolysis by phosphodiesterase enzymes (PDE) . Multiple PDE isoenzymes have been isolated from a variety of tissues and based on their kinetic characteristics, substrate specificity, sensitivity to endogenous regulators and susceptibility to inhibition by selective inhibitors have been divided into five distinct families (PDE I-V; Beavo, 1988; Beavo & Reifsnyder, 1990) . Of these PDE I, II and III can utilise both cyclic AMP and cyclic GMP as substrate, PDE IV is a cyclic ' Author for correspondence.
AMP-specific PDE and PDE V a cyclic GMP-specific PDE (Beavo, 1989; Beavo & Reifsnyder, 1990) . Although their relative proportions vary depending on species and airway generation, members of all five families have been detected in smooth muscle from canine (Trophy & Cieslinski, 1990) , bovine (Shahid et al., 1991) , guinea-pig (Takagi et al., 1992; Turner et al., unpublished observations) and human (de Boer et al., 1992; Giembycz et al., 1992; Cortijo et al., 1993) airway.
The bronchodilator activity and anti-asthma potential of xanthines is attributed, at least in part, to non-selective inhibition of multiple PDE activities (Torphy & Undem, 1991) . More recently, however, interest has focused on the potential of isoenzyme-selective PDE inhibitors as bronchodilator and anti-inflammatory agents. Selective inhibitors of the PDE III and IV isoenzymes are effective relaxants of guinea-pig trachea (Harris et al, 1989; Tomkinson et al., 1993) , canine trachealis (Torphy et al., 1988; , bovine trachea (PDE III inhibitors are only weakly active, Shahid et al., 1991) and human bronchus (de Boer et '." Macmillan Press Ltd, 1994 Cortijo et al., 1993) in vitro and have bronchodilator activity in the guinea-pig (Harris et al., 1989; Cortijo et al., 1993; Howell et al., 1993) and dog (Heaslip et al., 1991) in vivo. In contrast despite the presence of PDE V in the airway of all species so far studied, the PDE V inhibitor zaprinast alone is without effect on canine tracheal tone and at concentrations that retain selectivity for PDE V, is a relatively ineffective relaxant of bovine trachea (Hall et al., 1990; Shahid et al., 1991) and human bronchus (de Boer et al., 1992) in vitro. Nevertheless it is generally accepted that increases in intracellular cyclic GMP are causally related to relaxation of airway smooth muscle (Polson et al., 1985; Torphy & Undem, 1991) . In this regard both sodium nitroprusside and atrial naturetic peptide (ANP) increase cyclic GMP levels and potently relax bovine and canine tracheal smooth muscle (Lorenz & Wells, 1983; Torphy et al., 1985; Ishii & Murad, 1989) . Furthermore, zaprinast potentiates both sodium nitroprusside-induced relaxation of canine trachealis and the associated increase in cyclic GMP accumulation .
We have previously reported that SK&F 96231 (1,7.-dihydro-2-(2-propoxyphenyl)-6H-purin-6-one) is a potent and selective inhibitor of the cyclic GMP PDE V (Murray et al., 1991) . SK&F 96231 relaxes guinea-pig trachea precontracted with K+, histamine or the thromboxane-mimetic, U46619 and causes a slow time-dependent increase in the cyclic GMP content of guinea-pig lung strips, in vitro (Murray et al., 1991) . In vivo, SK&F96231 has been shown to produce a modest, short-lived inhibition of U44619-induced bronchoconstriction in anaesthetized guinea-pigs and is approximately 4 fold more potent than zaprinast in this regard (Murray et al., 1991) .
In the present study we have used SK&F 96231 to examine the role of PDE V in mediating bronchodilatation in the anaesthetized guinea-pig, a widely employed model of human asthma. In addition we have compared its activity to that of the PDE III inhibitors, siguazodan or SK&F 95654 and the PDE IV inhibitor, rolipram.
Methods
In vivo inhibition of histamine-induced bronchoconstriction in anaesthetized guinea-pigs Male Dunkin-Hartley guinea-pigs (450-570 g) were anaesthetized with sodium pentobarbitone (Sagatal, (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) Histamine-induced bronchoconstriction was assessed as the difference between the basal PIP and the maximum increase in PIP caused by histamine, each animal serving as its own control.
In a separate series of experiments, tracheae were removed at time intervals following infusion of SK&F 96231, SNP or their combination and snap frozen in liquid nitrogen and stored at -70'C prior to measurement of cyclic GMP levels. Cyclic nucleotides were extracted by addition of 1 ml cold 0.3 M perchloric acid to the frozen tissues; tissues were then finely chopped, in the perchloric acid, and homogenized (Polytron PTA7KI probe 4 x 10 s burst, setting 8). Following centrifugation, acid was removed from the supernatant by extraction with a 50/50 (v/v) mixture of tri-n-octylamine and freon. Cyclic GMP levels were estimated with a commercially available (Amersham) radioimmunoassay kit.
Protein estimations were determined by the Bio-Rad protein assay based on the method described by Bradford (1976) .
Guinea-pig isolated trachea
Male Dunkin-Hartley guinea-pigs weighing from 350-450 g were killed by cervical dislocation. Each trachea was rapidly excised, placed in oxygenated (95% 02, 5% CO2) KrebsHenseleit solution (composition in mM: NaC 118, KCl 4.7, NaHCO3 25, MgSO4 1.2, KH2SO4 1.2, D-glucose 5.5, CaCl2 2.5) at room temperature and trimmed free of adherent fat and connective tissue.
Each trachea was cut into rings containing 3 adjacent cartilage plates, the rings were opened opposite the trachealis and suspended in 25 ml organ baths containing Krebs solution at 37°C, under an initial load of 2.5 g. Following a 60 min equilibration period, tissues were primed for contractile activity by addition of 1 gM carbachol (CCh). This procedure was repeated 3 times after washing. 
Data analysis
The data are expressed as mean ± s.e.mean and were compared by Mann Whitney U test for unpaired observations. A two-tailed probability of <0.05 was considered significant. tt values for PDE inhibitors and salbutamol represent the time to 50% recovery of histamine responses.
Materials
All drugs and chemicals were obtained from Sigma or BDH Chemicals (both of Poole, Dorset). The cyclic GMP radioimmunoassay kit was from Amersham International (Amersham, Buckinghamshire). SK&F 96231 (1,7-dihydro-2-(2-propoxyphenyl)-6H purin-6-one), siguazodan (SK&F 94836 2-cyano-1 -methyl-3-[4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl]guanidine, SK&F 95654 (R,S-4,5-dihydro- . Under these latter conditions the inhibition of histamine-induced bronchoconstriction was rapid in onset, achieving a maximum within 5 min of starting the SK&F 96231 infusion; in addition doses which previously were devoid of inhibitory activity were found to cause > 50% inhibition of histamine bronchoconstriction in the presence of SNP. Administered directly into the airway, SK&F96231 (300 jg or 1 mg) caused a small, short-lived (4.9 ± 1.9%, t 6.6 ± 1.9 min and 9.9 ± 10%, t1 4.7 ± 2.3 min respectively) inhibition of the increase in pulmonary inflation pressure elicited by bolus injection of histamine (100 nmol kg-', i.v.).
SK&F 96231 however significantly inhibited the histamineinduced bronchoconstriction (40 ± 4% at 300 jlg and 59 ± 7% at 1 mg, n = 5, P< 0.05) in the presence of SNP (infused i.v. at a dose that alone was without effect on the histamine induced bronchoconstriction:-0.1 jmol kg-' min-'). There was however no effect of SNP on the duration of the inhibition.
In contrast to the potentiation of the antispasmogenic activity of SK&F 96231 by SNP, when the latter was administered by i.v. infusion, there was no potentiation of the effects of SK&F 96231 by SNP (300 ljg) when both were administered locally. In contrast whilst isosorbide dinitrate 4.7 ± 2.3 8.7 ± 1.7 3.7 ± 1.7 3, Table 1 ); at 300 jig, histamine responses were reduced by 91 ± 2% and 59 ± 10% respectively. The PDE III inhibitor, siguazodan (300 jig) was without effect on histamine responses but they were reduced 28± 5% by the PDE III inhibitor, SK&F 95654 (300 jig). There was a marked potentiation of the effects of rolipram in the presence of SK&F 95654 ( Figure 4 , Table 1 ).
Mean resting blood pressure in these experiments was 43.3 ± 1.4 mmHg systolic, 28.0 ± 1.14 diastolic (n = 55). Administration of salbutamol, SK&F 96231, SK&F 95654 and rolipram (or the combination of the latter two) into the airways was accompanied by a small (up to 10 mmHg), transient fall in blood pressure associated with disconnection of the animal from the ventilator. On recomencement of ventilation this was followed by a return to pre-dosing levels (n = 23) or by a small (11.5 ± 1.5 mmHg) but sustained increase in blood pressure (n = 16). The pressor response however was unrelated to either compound or dose, suggesting that it was a nonspecific event related to the dosing. Infusion Effect of SK&F96231 infusion on tracheal cyclic GMP levels in vitro and in vivo Previous observations indicate that SK&F 96231 elevates total cyclic GMP levels in guinea-pig lung strips in vitro (Murray et al., 1991) . Since interpretation of these data is complicated by the highly vascularized nature of this preparation, we have carried out studies to determine if SK&F 96231 also increases cyclic GMP levels in tracheal tissue in vitro and in vivo. The results are summarized in Tables 2 and  3 . In the isolated trachea, cyclic GMP levels were elevated above control (in the presence of carbachol) only at concentrations of SK&F 96231 that caused maximum relaxations of carbachol elevated tone. When administered by i.v. infusion in the anaesthetized guinea-pig, SK&F 96231 caused a doseand time-dependent increase in tracheal cyclic GMP levels that paralleled the time-course of inhibition of histamineinduced contractions. Table 4 shows the results of a study of the interaction of SK&F 96231 and SNP. When administered alone there was no effect of SNP (0.1 gmol kg' min ') on either the histamine responses or on tracheal cyclic GMP levels (measured at 5 min post-dose). Similarly SK&F 96231 (0.6 mg kg-' min ') by itself did not alter histamine-induced 0.68 ± 0.22* Bronchoconstriction was induced by i.v. injection of histamine (100 nmol kg-') at 5 min intervals. SNP was infused for 15 min prior to infusion of SK&F 96231 as in the functional studies. Effects of agents on the increase in pulmonary inflation pressure were measured 5 min after commencing the infusion of SK&F 96231. In separate experiments tracheae were removed at this time point, frozen in liquid nitrogen and assayed for cyclic GMP levels by radioimmunoassay. Assays were performed in triplicate and values are the mean of data from three separate experiments. *P<0.05 compared to control. relaxant activity of SK&F 96231 was not accompanied by a concomitant reduction in tracheal cyclic GMP levels ( Table  2 ). The spasmolytic activity of SK&F 96231 was unaffected by epithelium removal or by 1O pM methylene blue.
Discussion
Both SNP and SK&F 96231 elevate cyclic GMP levels in airway smooth muscle in vitro (Katsuki & Murad, 1977; Torphy et al., 1985; Ishii & Murad, 1989; Murray et al., 1991) ; however, whilst SNP stimulates the soluble guanylate cyclase directly (Waldman & Murad, 1987) the ability of PDE V inhibitors to elevate smooth muscle cyclic GMP levels, in vivo, might be expected to be dependent on the level of endogenous guanylate cyclase activity. Consistent with this hypothesis we have shown that SK&F 96231, infused i.v. at high doses, causes a slowly developing inhibition of histamine-induced bronchoconstriction which was accompanied by a parallel increase in tracheal cyclic GMP content. We consider therefore that the effects of SK&F 96231 on airway tone in vivo are likely to be a consequence of cyclic GMP accumulation. This conclusion is supported by the observation that the SK&F 96231 inhibition of histamine-induced bronchoconstriction and increase in tracheal cyclic GMP content was significantly enhanced in the presence of a sub-threshold infusion of SNP. Moreover at infusion rates of SK&F 96231 and SNP which alone were devoid of any inhibitory activity, their combination elicited a marked inhibition of histamine responses. Similarly, administered directly into the airway SK&F 96231 was largely without effect on the bronchoconstriction to histamine. This is consistent with its poor anti-spasmogenic activity when administered by i.v. bolus injection (32% inhibition of histamine induced bronchoconstriction at 1 mg kg-' i.v; unpublished observation). When coupled with a subthreshold i.v. infusion of SNP however, SK&F 96231 administered directly into the airways caused significant inhibition (40% at 300 fig, 62% at 1 mg). In addition, although SNP failed to potentiate the effects of SK&F 96231 when both agents were delivered by the inhaled route the less labile nitrovasodilator, isosorbide dinitrate, significantly potentiated its bronchorelaxant activity. This combined action, of agents that stimulate guanylate cyclase directly and SK&F 96231, particularly at doses, systemically or locally, that alone are without any anti-spasmogenic activity strongly suggests that even at mechanically silent doses of SK&F 96231, PDE V activity is inhibited. That this is only uncovered in the presence of guanylate cyclase stimulation therefore suggests that the antispasmogenic and spasmolytic activity of PDE V inhibitors, in vivo, is limited by guanylate cyclase activity.
Isoenzyme profiling of guinea-pig trachea (Turner, unpublished information; Tagaki et al., 1992) has shown that it contains at least two cyclic GMP hydrolytic activities, the Ca2+-calmodulin stimulated PDE I and the cyclic GMPspecific PDE V. We cannot rule out therefore the possibility that the poor spasmolytic activity of SK&F 96321 is due to hydrolysis of cyclic GMP by PDE's other than PDE V. However, since coupling SK&F 96231 with an exogenous stimulus to guanylate cyclase activity uncovered significant inhibition of bronchoconstriction, we consider it more likely that it is a consequence of low endogenous guanylate cyclase activity in the airway, perhaps due to the absence of an endogenous agonist.
In vitro studies also showed that the SK&F96231-and SNP-induced relaxations of guinea-pig trachea were functionally antagonized by high concentrations of carbachol (but not histamine, data not shown). Functional antagonism of relaxant responses by high concentrations of muscarinic agonists have previously been reported in canine and bovine tracheal smooth muscle for agents which elevate cyclic AMP:-prostaglandin E2, isoprenaline, forskolin, SK&F 94836, AH21-132; but not cyclic GMP (Torphy et al., 1983; 1988; Giembycz & Barnes, 1991) . The results of the present study demonstrated that, unlike canine trachea where the concentration of muscarinic agonist is reported to have little effect on the mechanical responses to SNP or 8-bromo cyclic GMP (Torphy et al., 1985) , in the guinea-pig trachea, the spasmolytic effects of SK&F 96231 and SNP are modified by the degree of muscarinic tone. In contrast the increase in intracellular cyclic GMP, stimulated by SK&F 96231, was unaffected; indeed, consistent with previous findings in canine tracheal smooth muscle (Katsuyama et al., 1990 ) carbachol alone stimulated a 2 fold increase in tracheal cyclic GMP levels. The attenuation of the spasmolytic activity of SK&F 96231 by high concentrations of carbachol therefore cannot be explained by a muscarinic receptor modulation of guanylate cyclase activity or phosphodiesterase activation. Torphy et al. (1988) have reported that methacholine suppresses the ability of SK&F 94836 to activate the cyclic AMP-dependent protein kinase (Torphy et al., 1985; 1988) . Our present results suggest that the functional antagonism of the relaxant activity of agents that elevate cyclic GMP may similarly operate at or beyond the level of the cyclic GMP-dependent protein kinase.
We have also shown that when administered directly into the airway, rolipram inhibits histamine-induced bronchoconstriction demonstrating that selective PDE IV inhibitors can act as bronchodilators when inhaled. The bronchodilator activity of rolipram however was only 60% of that to an equivalent dose of salbutamol (300 ytg) and was of a shorter duration. In contrast Underwood et al. (1993) have reported that rolipram fails to affect significantly histamine-induced contraction of guinea-pig isolated trachea at concentrations up to 1 pM. Furthermore, the same authors showed that rolipram only reduced histamine-induced bronchoconstriction at high doses (3-10mgkg-', i.v; Underwood et al., 1993) . Similarly, rolipram (3 mg kg-', i.v.) has been reported to elicit only a weak inhibition of the bronchoconstriction induced by aerosolized histamine (Howell et al., 1993) . Our present study therefore indicates that the anti-spasmogenic potency of rolipram, when delivered directly into the airway is approximately 30 fold greater than when it is given i.v.
The results of the present study also suggest that PDE III inhibitors, when administered into the airway are relatively ineffective in inhibiting histamine-induced bronchoconstriction. Nevertheless, the combination of rolipram and the PDE III inhibitor SK&F 95654, at doses that alone had only minimal effects on histamine responses, caused a marked inhibition of histamine-induced bronchoconstriction. This combined action of inhaled PDE III and IV inhibitors has, to our knowledge, not previously been reported in vivo but is in agreement with their reported interaction in guinea-pig isolated trachea (Harris et al., 1989) . The results suggest that both PDE III and PDE IV are involved in hydrolysis of cyclic AMP in the guinea-pig airway, in vivo, but that when only one isoenzyme is inhibited its ability to elevate intracellular cyclic AMP levels and thence to cause bronchodilatation is restricted by cyclic AMP hydrolysis through other PDE isoforms. The data suggest therefore that inhibitors of both PDE III and PDE IV may offer greater potential as bronchodilators in asthma than inhibitors of either isoenzyme alone.
In conclusion PDE V inhibitors alone are relatively weak inhibitors of histamine-induced bronchoconstriction in the anaesthetized guinea-pig. The enhancement of the inhibition of bronchoconstriction by coupling SK&F 96231 with either SNP or isosorbide dinitrate suggests that the poor activity of SK&F 96231 alone is secondary to low guanylate cyclase activity in the airway. The combination of PDE V inhibitor and guanylate cyclase agonist might therefore provide significant bronchodilator potential in asthma.
